Edition:
United Kingdom

Pain Therapeutics Inc (PTIE.OQ)

PTIE.OQ on NASDAQ Stock Exchange Global Select Market

4.24USD
13 Dec 2017
Change (% chg)

$0.01 (+0.36%)
Prev Close
$4.22
Open
$4.25
Day's High
$4.25
Day's Low
$4.17
Volume
5,671
Avg. Vol
64,203
52-wk High
$9.31
52-wk Low
$3.10

Chart for

About

Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company's lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company's other products is FENROCK. REMOXY is a... (more)

Overall

Beta: 2.17
Market Cap(Mil.): $28.03
Shares Outstanding(Mil.): 6.60
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Pain therapeutics reports Q3 loss per share $0.40

* Pain therapeutics reports third quarter 2017 financial results

01 Nov 2017

BRIEF-Pain Therapeutics announces upcoming meeting with FDA

* Pain Therapeutics - ‍U.S. FDA agreed to pre-nda guidance meeting to discuss co's NDA resubmission for remoxy er as a treatment for severe chronic pain​

30 Oct 2017

BRIEF-Pain Therapeutics announces successful Phase I clinical study for PTI-125

* Pain Therapeutics announces successful Phase I clinical study for PTI-125

24 Oct 2017

BRIEF-National Institute on Drug Abuse awards Pain Therapeutics $2.2 mln grant

* National Institute on Drug Abuse awards Pain Therapeutics $2.2 million grant Source text for Eikon: Further company coverage:

18 Sep 2017

BRIEF-Pain Therapeutics reports Q2 loss per share $0.64

* Pain Therapeutics reports Q2 2017 financial results and mid-year corporate update

09 Aug 2017

BRIEF-Pain Therapeutics announces FDA clears investigational new drug application for PTI-125

* Pain Therapeutics announces FDA has cleared an investigational new drug (IND) application for PTI-125

31 Jul 2017

Competitors

Earnings vs. Estimates